Medicare issues
Healthcare issues
Supply chain issues
Duration: January 1, 2014
to
December 31, 2023
General Issues: Health Issues , Budget/Appropriations , Medical/Disease Research/Clinical Labs , Medicare/Medicaid , Manufacturing , Taxation/Internal Revenue Code , Trade (Domestic & Foreign) , Veterans , Miscellaneous Tariff Bills
Spending: about $5,345,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2014: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Energy - Dept of, Nuclear Regulatory Commission (NRC), Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
Affiliated organizations: Elekta
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2023
Elekta, Inc. in-house lobbying effort was terminated on Jan. 22
Original Filing: 301537210.xml
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to value-based payment models for radiation therapy
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the security and cybersecurity of critical infrastructure and connected devices
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Supporting access to medical therapies
3rd Quarter, 2023
In Q3, Elekta, Inc. had in-house lobbyists. The report was filed on Oct. 19, 2023.
Original Filing: 301506350.xml
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to value-based payment models for radiation therapy
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the security and cybersecurity of critical infrastructure and connected devices
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Supporting access to medical therapies
Lobbying Issues
Issues pertaining to the study of radioisotopes in the delivery of health care services
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2023
In Q2, Elekta, Inc. had in-house lobbyists. The report was filed on July 20, 2023.
Original Filing: 301486745.xml
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to value-based payment models for radiation therapy
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the security and cybersecurity of critical infrastructure and connected devices
Agencies Lobbied
U.S. Senate U.S. House of Representatives Energy - Dept of
Lobbying Issues
Supporting access to medical therapies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to government trade policies
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
Lobbying Issues
Issues pertaining to the study of radioisotopes in the delivery of health care services
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2023
In Q1, Elekta, Inc. had in-house lobbyists. The report was filed on April 20, 2023.
Original Filing: 301460620.xml
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to value-based payment models for radiation therapy
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the security and cybersecurity of critical infrastructure and connected devices
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Supporting access to medical therapies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to government trade policies
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
Lobbying Issues
Issues pertaining to the study of radioisotopes in the delivery of health care services
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2022
In Q4, Elekta, Inc. had in-house lobbyists. The report was filed on Jan. 19, 2023.
Original Filing: 301432780.xml
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the Medicare Radiation Oncology Alternate Payment Model
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the security and cybersecurity of critical infrastructure and connected devices
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Supporting access to medical therapies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to government trade policies
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
3rd Quarter, 2022
In Q3, Elekta, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2022.
Original Filing: 301413269.xml
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the Medicare Radiation Oncology Alternate Payment Model
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the security and cybersecurity of critical infrastructure and connected devices
Agencies Lobbied
U.S. Senate U.S. House of Representatives Nuclear Regulatory Commission (NRC)
Lobbying Issues
Supporting access to medical therapies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to government trade policies
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
2nd Quarter, 2022
In Q2, Elekta, Inc. had in-house lobbyists. The report was filed on July 20, 2022.
Original Filing: 301395008.xml
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the Medicare Radiation Oncology Alternate Payment Model
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the cybersecurity of critical infrastructure and connected devices
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Supporting access to medical therapies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to government trade policies
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
1st Quarter, 2022
In Q1, Elekta, Inc. had in-house lobbyists. The report was filed on April 20, 2022.
Original Filing: 301372181.xml
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the Medicare Radiation Oncology Alternate Payment Model
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the cybersecurity of critical infrastructure and connected devices
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Supporting access to medical therapies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to government trade policies
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
4th Quarter, 2021
In Q4, Elekta, Inc. had in-house lobbyists. The report was filed on Jan. 5, 2022.
Original Filing: 301320184.xml
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the Medicare Radiation Oncology Alternate Payment Model
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the cybersecurity of critical infrastructure and connected devices
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Supporting access to medical therapies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to government trade policies
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
3rd Quarter, 2021
In Q3, Elekta, Inc. had in-house lobbyists. The report was filed on Oct. 14, 2021.
Original Filing: 301299241.xml
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the Medicare Radiation Oncology Alternate Payment Model
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the cybersecurity of critical infrastructure and connected devices
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Supporting access to medical therapies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to government trade policies
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
2nd Quarter, 2021
In Q2, Elekta, Inc. had in-house lobbyists. The report was filed on July 20, 2021.
Original Filing: 301289726.xml
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the Medicare Radiation Oncology Alternate Payment Model
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the cybersecurity of critical infrastructure and connected devices
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Supporting access to medical therapies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2021
In Q1, Elekta, Inc. had in-house lobbyists. The report was filed on April 20, 2021.
Original Filing: 301265471.xml
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the Medicare Radiation Oncology Alternate Payment Model
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Supporting access to medical therapies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2020
In Q4, Elekta, Inc. had in-house lobbyists. The report was filed on Jan. 21, 2021.
Original Filing: 301245821.xml
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the Medicare Radiation Oncology Alternate Payment Model
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Supporting access to medical therapies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2020
In Q3, Elekta, Inc. had in-house lobbyists. The report was filed on Oct. 19, 2020.
Original Filing: 301215786.xml
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the Medicare Radiation Oncology Alternate Payment Model
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Supporting access to medical therapies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2020
In Q2, Elekta, Inc. had in-house lobbyists. The report was filed on July 14, 2020.
Original Filing: 301187503.xml
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the Medicare Radiation Oncology Alternate Payment Model
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Supporting access to medical therapies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to government trade policies
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
1st Quarter, 2020
In Q1, Elekta, Inc. had in-house lobbyists. The report was filed on April 13, 2020.
Original Filing: 301165980.xml
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the Medicare Radiation Oncology Alternate Payment Model
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Supporting access to medical therapies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to government trade policies
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
4th Quarter, 2019
In Q4, Elekta, Inc. had in-house lobbyists. The report was filed on Jan. 9, 2020.
Original Filing: 301104101.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to the medical device excise tax [Further Consolidated Appropriations Act, 2020 (HR 1865, Sec. 501)]
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Supporting access to medical therapies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to government trade policies
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
3rd Quarter, 2019
In Q3, Elekta, Inc. had in-house lobbyists. The report was filed on Oct. 8, 2019.
Original Filing: 301063770.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to the medical device excise tax
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Supporting access to medical therapies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to government trade policies
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
2nd Quarter, 2019
In Q2, Elekta, Inc. had in-house lobbyists. The report was filed on July 10, 2019.
Original Filing: 301044296.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to the handling of radiological sources
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to the medical device excise tax
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Supporting access to medical therapies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to government trade policies
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
1st Quarter, 2019
In Q1, Elekta, Inc. had in-house lobbyists. The report was filed on April 17, 2019.
Original Filing: 301027339.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to the handling of radiological sources
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to the medical device excise tax
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Supporting access to medical therapies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to government trade policies
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
4th Quarter, 2018
In Q4, Elekta, Inc. had in-house lobbyists. The report was filed on Jan. 18, 2019.
Original Filing: 301009273.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to the handling of radiological sources
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to the medical device excise tax
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Supporting access to medical therapies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to government trade policies
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
3rd Quarter, 2018
In Q3, Elekta, Inc. had in-house lobbyists. The report was filed on Oct. 9, 2018.
Original Filing: 300983716.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to the handling of radiological sources
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to the medical device excise tax
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Supporting access to medical therapies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues pertaining to government trade policies
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Miscellaneous Tariff Bills
2nd Quarter, 2018
In Q2, Elekta, Inc. had in-house lobbyists. The report was filed on July 20, 2018.
Original Filing: 300974546.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to the handling of radiological sources
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to the medical device excise tax
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Supporting access to medical therapies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2018
In Q1, Elekta, Inc. had in-house lobbyists. The report was filed on April 18, 2018.
Original Filing: 300946952.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to the handling of radiological sources
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to the medical device excise tax
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Supporting access to medical therapies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2017
In Q4, Elekta, Inc. had in-house lobbyists. The report was filed on Jan. 19, 2018.
Original Filing: 300929796.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to the handling of radiological sources
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to the medical device excise tax; destination-based tax proposals [HR 1/PL 115-97]
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
In Q3, Elekta, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2017.
Original Filing: 300914167.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the medical device excise tax
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to the handling of radiological sources
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2017
In Q2, Elekta, Inc. had in-house lobbyists. The report was filed on July 18, 2017.
Original Filing: 300887932.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the medical device excise tax; Issues addressing health care access and trade policy
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to the handling of radiological sources
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2017
In Q1, Elekta, Inc. had in-house lobbyists. The report was filed on April 18, 2017.
Original Filing: 300868163.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the medical device excise tax; Issues addressing health care access and trade policy
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to the handling of radiological sources
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2016
In Q4, Elekta, Inc. had in-house lobbyists. The report was filed on Jan. 17, 2017.
Original Filing: 300847728.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the medical device excise tax; Issues addressing health care access and trade policy
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to the handling of radiological services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2016
In Q3, Elekta, Inc. had in-house lobbyists. The report was filed on Oct. 19, 2016.
Original Filing: 300833090.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the medical device excise tax
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to the handling of radiological services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2016
In Q2, Elekta, Inc. had in-house lobbyists. The report was filed on July 25, 2016.
Original Filing: 300822598.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the medical device excise tax
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to the handling of radiological services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2016
In Q1, Elekta, Inc. had in-house lobbyists. The report was filed on April 20, 2016.
Original Filing: 300801264.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the medical device excise tax
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues pertaining to the handling of radiological services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2015
In Q4, Elekta, Inc. had in-house lobbyists. The report was filed on Jan. 19, 2016.
Original Filing: 300776819.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to oncology treatment products and services; Issues pertaining to the medical device excise tax [Consolidated Appropriations Act 2016 (HR 2029)]
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2015
In Q3, Elekta, Inc. had in-house lobbyists. The report was filed on Oct. 19, 2015.
Original Filing: 300758595.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
2nd Quarter, 2015
In Q2, Elekta, Inc. had in-house lobbyists. The report was filed on July 20, 2015.
Original Filing: 300744025.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
1st Quarter, 2015
In Q1, Elekta, Inc. had in-house lobbyists. The report was filed on April 20, 2015.
Original Filing: 300722652.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2014
In Q4, Elekta, Inc. had in-house lobbyists. The report was filed on Jan. 20, 2015.
Original Filing: 300702411.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2014
In Q3, Elekta, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2014.
Original Filing: 300684620.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2014
In Q2, Elekta, Inc. had in-house lobbyists. The report was filed on July 21, 2014.
Original Filing: 300665290.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
1st Quarter, 2014
In Q1, Elekta, Inc. had in-house lobbyists. The report was filed on April 17, 2014.
Original Filing: 300638487.xml
Lobbying Issues
Issues related to oncology treatment products and services
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS)
1st Quarter, 2014
Elekta, Inc. filed a lobbying registration on Feb. 9, 2014 for in-house lobbying efforts, effective Jan. 1, 2014.
Original Filing: 300630190.xml
Issue(s) they said they’d lobby about: Issues related to oncology treatment products and services; Issues pertaining to medical device tax .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate